Business Context and Reporting Period
Company: AirSculpt Technologies, Inc. (AIRS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: AirSculpt operates a network of 31 centers across 20 U.S. states and Canada, providing minimally invasive body contouring procedures (e.g., fat removal, skin tightening, fat transfer) exclusively through its proprietary AirSculpt® method. The company operates as a holding company, providing management services to Professional Associations owned by surgeons.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $151.8 million | $180.4 million | (15.8)% |
| Net Loss | $(11.7) million | $(8.0) million | Widened |
| Adjusted EBITDA | $15.1 million | $21.0 million | (28.1)% |
| Adjusted EBITDA Margin | 9.9% | 11.6% | (1.7) pts |
| Operating Cash Flow | $3.1 million | $11.4 million | (72.7)% |
| Cash and Equivalents | $8.4 million | $8.2 million | N/A |
| Total Debt (Principal) | $57.0 million | $70.8 million | Reduced |
| Procedures Performed | 11,852 | 14,036 | (15.6)% |
| Revenue Per Case | $12,809 | $12,849 | (0.3)% |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $28.5 million (15.8%) primarily due to a 15.6% drop in case volume. Same-center case volume declined 22.1% year-over-year.
- Increased Losses: Net loss widened to $11.7 million from $8.0 million in 2024, driven by lower revenue and significant non-recurring charges.
- Impairment and Closure Costs: The company recorded a $4.6 million loss on impairment of long-lived assets (primarily a Salesforce implementation project) and $2.2 million in costs related to the closure of its London facility.
- Debt Restructuring: In March 2025, the company amended its credit agreement (Third Amendment), modifying financial covenants and increasing interest rate margins. The company prepaid $10.0 million of term loan principal in June 2025 using proceeds from an equity offering.
- Equity Raises: The company raised approximately $13.8 million via an underwritten public offering and $5.6 million via an at-the-market (ATM) offering program in 2025.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management is focusing on returning to revenue growth through optimized marketing investments, improved sales execution, expanded consumer financing options, and new product innovation (specifically skin tightening). The company has paused de novo center openings to improve liquidity and unit economics.
Key Risks & Contingencies:
- Liquidity & Debt: The company faces significant leverage with a Consolidated Leverage Ratio covenant requiring reduction to 2.25x by March 31, 2026. Debt matures in May 2027, and refinancing is not guaranteed.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to lease accounting (ASC 842), requiring restatement of prior periods. Remediation is ongoing.
- Competition: Increased market acceptance of weight-loss drugs (GLP-1s) poses a competitive threat, though management believes it may also drive demand for body contouring.
- Regulatory: Risks related to corporate practice of medicine laws and fee-splitting regulations in various states.
Investor Verification Checklist
- Liquidity Runway: Verify if current cash ($8.4M) plus revolver availability ($5.0M) is sufficient to meet the $7.5M minimum liquidity covenant and fund operations until debt maturity or refinancing.
- Debt Covenant Compliance: Confirm the company's ability to meet the tightened Consolidated Leverage Ratio (3.25x for Q4 2025, 2.75x for Q1 2026) and Fixed Charge Coverage Ratio.
- Restatement Impact: Review the specific adjustments made to prior period financial statements due to the lease accounting material weakness.
- Case Volume Trends: Monitor same-center volume metrics to determine if the 22.1% decline is stabilizing or accelerating.
- Equity Dilution: Assess the impact of ongoing ATM offerings and potential future equity raises required to service debt.